Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...
Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...
With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. Late last week, the FDA ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...
Patients with Huntington's disease might have hope for relief from chorea, a key cause of disability and death in individuals afflicted with the hereditary disease. On Friday, the FDA approved ...
The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD. Positive topline data were announced from a phase 3 study evaluating the ...
Neurocrine Biosciences announced data from a phase 3 trial of Ingrezza that showed it reduced chorea severity among patients with Huntington’s disease. The trial, called KINECT-HD, examined the ...
A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback